eligibility_summary
Inclusion: Adults ≥18 with unresectable SCLC/LCNEC (incl combined) after ≥1 prior line and progressed/intolerant/declining care, tumor tissue, measurable disease (RECIST 1.1), ECOG 0–1, adequate organs, WOCBP negative test, contraception and no gamete donation ×1 yr. Exclusion: prior cell/gene or DLL3 therapy, lepto/active brain mets (treated/stable), major cardiac disease, serious infection or uncontrolled HIV/HBV/HCV, unresolved ≥G2 tox, pregnancy/lactation, prior HSCT/organ transplant.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: LB2102, an autologous, gene‑modified cellular therapy (CAR T cells) engineered to express a chimeric antigen receptor targeting DLL3. Mechanism of action: CAR binding to DLL3 on tumor cells triggers T‑cell activation, expansion, cytokine release, and cytotoxic killing (perforin/granzyme) of DLL3‑positive cancer cells, independent of native TCR. Targets: DLL3 (Delta‑like ligand 3), an inhibitory Notch ligand aberrantly overexpressed on small cell lung cancer and large cell neuroendocrine carcinoma with limited normal tissue expression. Cells/pathways: DLL3/Notch axis on neuroendocrine tumor cells, effector CD4+/CD8+ T‑cell cytotoxic signaling.